Actively Recruiting
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
Led by University of Illinois at Chicago · Updated on 2026-05-01
40
Participants Needed
2
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to better understand how time restricted eating (eating all food in an 8 hour window) can help a person receiving chemotherapy treatment for breast cancer, stages I-IV. The aim is to find out if time restricted is feasible and acceptable to individuals starting chemotherapy for breast cancer. We will test 3 different eating window options compared to a control group for 24 weeks.
CONDITIONS
Official Title
Feasibility and Acceptibility of a Multi-site Trial of Time Restircted Eating During Chemotheraply for Breast Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 25 to 99 years at time of consent
- English or Spanish language speakers (based on interpreter availability)
- ECOG performance status 0 or 1
- Histologically confirmed breast cancer Stage I-III or Stage IV with medical oncology approval
- Adequate organ function with absolute neutrophil count 21 1,500/bcL
- All screening labs obtained within 30 days prior to registration
- Ability to provide written informed consent and HIPAA authorization
- Women of childbearing potential must have a negative serum or urine pregnancy test per guidelines
- Ability to understand and comply with study procedures for entire study duration as determined by enrolling physician
You will not qualify if you...
- Women with type 1 diabetes or insulin-dependent type 2 diabetes
- Women with BMI greater than 45 kg/m2 or less than 18.5 kg/m2
- Women who are pregnant or nursing (negative pregnancy test required)
- Shift workers
- History of eating disorders
- Significant weight gain or loss over 4 kg within 3 months prior to study
- Uncontrolled HIV/AIDS or active viral hepatitis
- Prior malignancy within 5 years, recent chemotherapy, or concurrent malignancy interfering with study
- Breast cancer recurrence as classified by treating oncologist
- Mental or medical conditions preventing informed consent or participation
- Other major comorbidities as determined by study principal investigator
- Illicit drug use within 3 months or excessive alcohol use (more than 2 drinks/day)
- Current participation in weight loss programs or use of weight loss medications including GLP-1
- History of myocardial infarction, congestive heart failure, chronic hepatitis, cirrhosis, chronic pancreatitis, or solid organ transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States, 60611
Actively Recruiting
2
University of Illinois Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
K
Kelsey Gabel, RD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here